Myo-Inositol for Women: PCOS, Fertility, and Insulin Sensitivity
Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Summary
Myo-inositol is a sugar-alcohol that acts as a secondary messenger for insulin signalling and follicle-stimulating hormone. It's the single most-studied natural intervention for polycystic ovary syndrome (PCOS). At 2 g twice daily (usually combined with D-chiro-inositol at a 40:1 ratio), it improves insulin sensitivity, cycle regularity, ovulation rate, and androgen markers in PCOS. Multiple RCTs show effect sizes comparable to metformin for a subset of patients, with fewer GI side effects. It's also used off-label for gestational diabetes prevention and for pre-IVF egg quality support. Safety is excellent. Evidence level: strong for PCOS; moderate for fertility outcomes.
Key facts
| Studied dose range | 2 g twice daily myo-inositol (± 50 mg D-chiro-inositol; 40:1 ratio is standard) |
|---|---|
| Common forms | Powder (best for grams-per-day dosing), capsules (many capsules needed) |
| Evidence level | Strong |
| Main interaction risks | Very well tolerated. Mild GI at high doses. |
What the research shows
Mechanism: insulin and FSH second messenger
Myo-inositol phosphoglycan mediators are downstream of both insulin and FSH receptors. In PCOS, tissue-level inositol depletion (with urinary wasting of myo-inositol and a shifted myo:D-chiro ratio) is a leading biochemical explanation for the coexisting insulin resistance and ovulatory dysfunction. Repletion at 2 g twice daily normalises intracellular signalling within roughly 8-12 weeks, which aligns with the timescale on which ovulation and cycle regularity return in trials.
Unfer 2017 meta-analysis (PCOS)
Unfer et al. (Endocrine Journal 2017, updated from 2016) pooled 9 RCTs of inositol in PCOS. Myo-inositol significantly reduced HOMA-IR, fasting insulin, free testosterone and LH:FSH ratio, and increased ovulation rate versus placebo. Effect sizes for HOMA-IR were in the range typically seen with lifestyle intervention plus low-dose metformin.
Facchinetti 2019 head-to-head vs metformin
Facchinetti et al. (Gynecol Endocrinol 2019) meta-analyzed head-to-head RCTs of inositol versus metformin in PCOS. Metabolic markers (HOMA-IR, BMI, testosterone) and ovulation rates were statistically equivalent, but the metformin arm had substantially higher GI adverse events and drop-outs. This is the strongest justification for offering myo-inositol as a first-line option in patients who cannot tolerate metformin.
Oocyte quality and IVF outcomes
Zheng et al. (Gynecol Endocrinol 2017) and multiple pre-IVF cohorts showed that 2 g BID myo-inositol plus 200-400 mcg folic acid for 3 months before stimulation improved oocyte maturation rate, reduced immature (GV) oocytes, and modestly improved fertilization rate in women with PCOS undergoing ICSI. Papaleo et al. (Fertil Steril 2009) previously showed similar improvements in gonadotropin dose required.
Gestational diabetes prevention
In three Italian RCTs (D'Anna et al., Diabetes Care 2013 and 2015; Matarrelli et al., J Matern Fetal Neonatal Med 2013) in women at high GDM risk (obesity, family history, prior GDM, or PCOS), 2 g BID myo-inositol from the first trimester reduced GDM incidence by roughly 50-65%. This is one of the few nutraceutical interventions with a positive Cochrane signal for GDM prevention.
The 40:1 myo:D-chiro ratio
Nordio & Proietti (Eur Rev Med Pharmacol Sci 2012) showed that a 40:1 myo:D-chiro ratio outperformed either isoform alone for combined metabolic and reproductive endpoints. The ratio was chosen because it mirrors the physiologic plasma ratio in healthy women; PCOS is characterised by relative myo-inositol depletion with preserved or elevated D-chiro.
Safety and pregnancy exposure
Cumulative pregnancy exposure across GDM prevention trials exceeds several thousand women without safety signals for the mother or fetus. Adverse events across the entire literature are almost exclusively mild GI (bloating, loose stools) at doses above 4 g/day and typically resolve with dose splitting.
Turn this evidence into a personal safety check for Myo-Inositol.
The interaction checker cross-references Myo-Inositol against HRT, birth control, thyroid medication, SSRIs, and every other item in your stack — using the same clinical sources cited above.
Check Myo-Inositol on the interaction checkerInteractions
Interaction risk is what makes women's-health supplements uniquely tricky — HRT, birth control, thyroid medication and SSRIs all share metabolic pathways with common botanicals. Each item below lists the mechanism and what to actually watch for.
- MetforminMechanism: Both improve insulin sensitivity — additive effect; some clinicians combine.Watch for: Monitor glucose; combining is safe and often synergistic.Check Myo-Inositol + Metformin on the interaction checker
- Fertility medication (letrozole, clomid)Mechanism: No pharmacokinetic conflict; often combined in PCOS protocols.Watch for: None specific.Check Myo-Inositol + Fertility medication (letrozole, clomid) on the interaction checker
- Birth control (COCs)Mechanism: No known interaction. Some PCOS patients use both.Watch for: None specific.Check Myo-Inositol + Birth control (COCs) on the interaction checker
- Thyroid medicationMechanism: No known interaction.Watch for: None specific.Check Myo-Inositol + Thyroid medication on the interaction checker
- InsulinMechanism: Additive glucose-lowering.Watch for: Monitor glucose closely if diabetic on insulin.Check Myo-Inositol + Insulin on the interaction checker
- SSRIs and lithiumMechanism: Very high inositol doses have been tested in psychiatric conditions with mixed results; no PK conflict.Watch for: None specific at PCOS doses.Check Myo-Inositol + SSRIs and lithium on the interaction checker
Who should be cautious
- Type 1 or insulin-dependent Type 2 diabetes — monitor glucose closely.
- Pregnancy — appears safe and is often specifically used; stay under obstetric supervision.
- Give it 3 months at 2 g BID before judging PCOS effect.
- Products labeled 'inositol blend' without stated myo:D-chiro ratio can vary widely; specify the ratio.
FAQ
How does myo-inositol help PCOS?
Myo-inositol acts as a secondary messenger for insulin and FSH. In PCOS — where insulin resistance drives androgen excess and ovulatory dysfunction — restoring inositol signalling improves insulin sensitivity, lowers androgens, and often restores ovulation. Effects appear at 3 months in most trials.
Myo-inositol or metformin for PCOS?
Meta-analyses show comparable metabolic and ovulation outcomes for the two. Inositol has better GI tolerability. Metformin has more decades of data and is cheaper. Many clinicians combine both. Discuss with your reproductive endocrinologist.
What ratio of myo-inositol to D-chiro-inositol?
The 40:1 ratio (2000 mg myo + 50 mg D-chiro) is the most studied. It mirrors the ratio found naturally in plasma. Products using different ratios have less evidence and, in some cases, worse outcomes than pure myo-inositol.
Does myo-inositol interact with birth control?
No — no known interaction. Some PCOS patients on birth control add myo-inositol for insulin and metabolic support.
Can I take myo-inositol during pregnancy?
Appears safe and is specifically used for gestational diabetes prevention in high-risk women. Stay under obstetric supervision.
Where can I check myo-inositol interactions?
Use the DoseRoutine interaction checker at doseroutine.com/interaction-checker to add every fertility supplement plus your prenatal, thyroid medication, or fertility prescription in one view.
Taking Myo-Inositol alongside HRT, birth control, or other supplements?
Get access to all DoseRoutine tools — check your full routine for interactions, log doses and get reminders.
Sign up freeSources
- Unfer V et al. Endocrine J 2017 - Inositols in PCOS: updated meta-analysis.
- Facchinetti F et al. Gynecol Endocrinol 2019 - Inositol vs metformin in PCOS meta-analysis.
- D'Anna R et al. Diabetes Care 2013 - Myo-inositol for GDM prevention in obese pregnant women.
- D'Anna R et al. Diabetes Care 2015 - Myo-inositol GDM prevention in women with family history.
- Papaleo E et al. Fertil Steril 2009 - Myo-inositol reduces gonadotropin requirement in IVF.
- Zheng X et al. Gynecol Endocrinol 2017 - Myo-inositol + folic acid pre-ICSI in PCOS.
- Nordio M, Proietti E. Eur Rev Med Pharmacol Sci 2012 - 40:1 myo:D-chiro ratio in PCOS.
Source: DoseRoutine Library — doseroutine.com/library/womens-health/myo-inositol